In a recent Genetic Engineering & Biotechnology News CDMO round-up, Samsung Biologics leaders shared actionable perspectives on overcoming critical hurdles in next-generation therapeutics—from formulation instabilities and capacity shortages to global supply chain vulnerabilities. Navigating complex modalities demands shifting away from transactional vendor models toward specialized, quality-driven CDMO partnerships.
By uniting advanced developability platforms, AI-driven manufacturing, and a resilient, diversified production network, Samsung Biologics mitigates execution risks, streamlines tech transfers, and prevents costly delays. Explore featured insights from Joon Ho Hwang (VP of Business Strategy), Jinhan Kim (VP of AX), and Derrick Katayama (Associate Director of Formulation Development) on driving bioprocessing resilience and digital transformation.
In a recent Genetic Engineering & Biotechnology News CDMO round-up, Samsung Biologics leaders shared actionable perspectives on overcoming critical hurdles in next-generation therapeutics—from formulation instabilities and capacity shortages to global supply chain vulnerabilities. Navigating complex modalities demands shifting away from transactional vendor models toward specialized, quality-driven CDMO partnerships.
By uniting advanced developability platforms, AI-driven manufacturing, and a resilient, diversified production network, Samsung Biologics mitigates execution risks, streamlines tech transfers, and prevents costly delays. Explore featured insights from Joon Ho Hwang (VP of Business Strategy), Jinhan Kim (VP of AX), and Derrick Katayama (Associate Director of Formulation Development) on driving bioprocessing resilience and digital transformation.
Share article
Related Content